ClinicalTrials.gg
Enrolling by invitationNCT07186088Updated Oct 29, 2026

Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies

An interventional study of Eyerising RS-200-2A and Eyerising SLX-1A in Myopia, sponsored by Ruihua Wei. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Ruihua Wei · Not applicable, Interventional, and Treatment

Updated Oct 29, 2026Now Enrolling by invitationPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Myopia with a site in China — 81 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.

Planned enrollment
126th of 154
60 · median 149
Started
2025
with 20 others
No phase
135 of 220
55 open now
Primary completion
2026-06
later than 40 of 100 live
Registered
180th of 220
by date
Lead sponsor
5 of 220
Ruihua Wei

Among the 220 studies in Myopia with a site in China, this one is the 126th largest by planned enrollment of the 154 interventional ones that give a count, is one of 21 that started in 2025, is one of 135 with no phase, reaches primary completion later than 40 of the 100 other live ones, and was the 180th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

81 of the 220 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light

Read the detailed description

The experiment will be divided into two phases. In the first phase, the subjects will be randomly grouped using laser equipment, LED equipment and control group. Each experimental group will be exposed to the red light twice a day for one month. The second stage involves self-comparison of the laser equipment, with the usage frequencies being once a day and three times a day.

To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light in different devices and frequencies, as well as its impact on the axial length, spherical equivalent refraction and choroidal thickness of myopia progression.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-35 years old, gender not limited; Obtained .

Exclusion criteria

Exclusion Criteria:

  • Obvious strabismus and amblyopia
  • With congenital eye disease, such as congenital cataract, congenital retinal disease
  • Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
  • Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
  • Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
  • Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP>21mmHg or binocular IOP difference ≥5mmHg)
  • Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
  • Optic nerve damage or congenital optic nerve dysfunction
  • Can not be regularly checked
  • The adjustment range is less than 8D or obvious near difficulties
  • Other reasons researchers think it is not suitable for inclusion in researchers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    The Laser Group

    Use Eyerising (RS-200-2A), 1 time,2 times or 3 times a day

    Device: Eyerising RS-200-2A

  • Experimental
    The LED Group

    Use Eyerising(SLX-1A), 2 times a day

    Device: Eyerising SLX-1A

  • No intervention
    Control

Interventions

  • DeviceEyerising RS-200-2A

    Eyerising RS-200-2A,1 time,2 times, 3 times a day

  • DeviceEyerising SLX-1A

    Eyerising SLX-1A, 2 times a day

06

What researchers measure

Primary outcomes

  1. Axial length

    Time frame: From enrollment to the end of treatment up to 7 months

Secondary outcomes

  1. Spherical equivalent

    Time frame: From enrollment to the end of treatment up to 7 months

  2. Choroidal thickness

    Time frame: From enrollment to the end of treatment up to 7 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jun 2026, 9 months.

Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 9 months is below that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Mar 2026 → Jun 2026 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2025
First posted
Sep 22, 2025
StartActual
Sep 20, 2025
Primary completionActual
Jun 20, 2026was Mar 2026
CompletionEst.
Dec 31, 2026was Jun 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 29, 2026
Primary completion
Mar 20, 2026→Jun 20, 2026 (actual)
Oct 29, 2026
Study completion
Jun 20, 2026→Dec 31, 2026
Oct 29, 2026
Enrollment
30→60
Oct 29, 2026
Interventions
Added Device: Eyerising SLX-1A; removed Device: Airdoc Sky-n1201. Arms added: Control
Oct 29, 2026
Contact
No study contact listed any more: removed l•••@163.com · •••8756
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Tianjin Medical University Eye Hospital · Tianjin, ChinaContact removed l•••@163.com · •••8756
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Enrolling by invitation
    Primary completion Mar 20, 2026→Jun 20, 2026 (now actual)
    Study completion Jun 20, 2026→Dec 31, 2026
    Enrollment 30→60
    Interventions Added Device: Eyerising SLX-1A; removed Device: Airdoc Sky-n1201. Arms added: Control
    Contact No study contact listed any more: removed l•••@163.com · •••8756
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Tianjin Medical University Eye Hospital · Tianjin, ChinaContact removed l•••@163.com · •••8756
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07186088
Lead sponsor
Ruihua Wei
Collaborators
Tianjin Medical University Eye Hospital
Responsible party
Ruihua Wei (Professor, Tianjin Medical University Eye Hospital) — Sponsor-investigator
First posted
Sep 22, 2025
Start date
Sep 20, 2025
Primary completion
Jun 20, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Ruihua Wei
principal investigator · Tianjin Medical University Eye Hospital, Tianjin, Tianjin 120120 Recruiting

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion